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The  available  databases  that  catalogue  information  on  traditional  Chinese  medicines  are reviewed  in
terms  of  their  content  and  utility  for in-silico  research  on  Chinese  herbal  medicines,  as  too  are  the  various
protein  database  resources,  and  the  software  available  for  use  in  such  studies.  The  software  available
for  bioinformatics  and  ‘omics  studies  of  Chinese  herbal  medicines  are  summarised,  and  a  critical  eval-vailable online 2 February 2012
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uation  given  of  the  various  in-silico  methods  applied  in  screening  Chinese  herbal  medicines,  including
classiﬁcation  trees,  neural  networks,  support  vector  machines,  docking  and  inverse  docking  algorithms.
Recommendations  are  made  regarding  any  future  in-silico  studies  of  Chinese  herbal  medicines.
© 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.hinese Herbal medicine
. Introduction
With the goal of establishing guidelines for good practice in in-
ilico research into traditional Chinese medicines (TCM), the WP4
orking party of the FP7-funded European consortium for GP-TCM
Good Practice in Traditional Chinese Medicine Research in the Post-
enomic Era) (Uzuner et al., 2010) deemed it appropriate ﬁrst of all
o draw up a catalogue of the various resources currently available,
nd then to review the use of such resources in the in-silico TCM
esearch reported in the literature to date. The computing resources
onsidered included the various databases currently available and
he software that has been or might be used in analyses of these
ata. The various different kinds of databases identiﬁed as rele-
ant included those holding ethnobotanical and/or chemical and/or
harmacological and/or toxicological data on the herbs used in
hinese medicine, as well as those that hold data on known or
otential molecular targets for the herbal constituents. The soft-
are tools considered as relevant included programs that provide
or (a) virtual screening of natural product libraries and chemical
ibraries, (b) pattern recognition, (c) bioinformatics studies relat-
ng to TCM and (d) the various data visualisation and statistical
nalysis packages for proteomics/genomics/metabolomics studies
nvolving TCM.
∗ Corresponding author. Tel.: +44 020 7848 4827; fax: +44 020 7848 4800.
E-mail address: dave.barlow@kcl.ac.uk (D.J. Barlow).
378-8741     © 2012 Elsevier Ireland Ltd.  
oi:10.1016/j.jep.2012.01.041
Open access under CC BY-NC-ND license.2. Terminology and communication problems between
specialist and non specialist
Preliminary discussions of the in-silico WP4  working party
focussed on the problems of terminology, and the difﬁculties asso-
ciated with performing scientiﬁcally sound and fruitful in-silico
studies in Chinese herbal medicines (CHM) research. For the pur-
poses of the review, in-silico studies were deﬁned as those involving
virtual screening and/or cheminformatics, but more widely would
also include those involving bioinformatics and the various differ-
ent types of ‘omics’ studies. The view was  universally held that any
such studies could not be fruitfully performed by non-specialists
– even though the software tools were often easily accessed and
easily used by those unfamiliar with computational chemistry. It
was  unanimously accepted that the performance of in-silico studies
in CHM research necessitated close interaction between compu-
tational chemists and CHM experimentalists. Such interaction is
common in the cross-disciplinary areas of molecular pharmacol-
ogy and structural biology, and in-silico CHM research would thus
present no exception.
3. Catalogue of existing databasesIt is vitally important to any in-silico studies of CHM that the
associated phytochemical data are available in a format suitable for
virtual screening (VS) or other informatics applications. Over recent
years the information available for Chinese herbs has increased
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Table 1
Catalogue of databases holding botanical information on TCM herbs and/or the composition of TCM formulae and their usage and/or information on the phytochemical
constituents of plants (including those used in CHM).
Database Content Source URL
TCM and chemical structure data
TCM Database@Taiwan Chinese medicine database that
contains 3-D structural information of
TCM constituents – ready for molecular
docking simulation (database currently
holds 37,170 (32,364 non-duplicate)
TCM compounds from 352 TCM)
Chen (2011) http://tcm.cmu.edu.tw/review.php?menuid=3
China Natural Products Database
(CNPD)
Information on Chinese natural
products including >40,000 structures.
Full set of structures
Shen et al. (2003) http://www.neotrident.com
3D  Structure Database of Components
from Chinese Herbs
3D structures (>10,000) from Chinese
herbs (>2000), with descriptors and
data on clinical uses. Full set of
structures
Qiao et al. (2002) –
Comprehensive Herbal Medicine
Information System for Cancer
(CHMIS-C)
Integrated information on cancer
molecular targets, Chinese herbal
recipes and phytochemical
constituents. Some structures
Fang et al. (2005) http://sw16.im.med.umich.edu/chmis-c/
Chinese herbal constituents database
(CHCD) and Bioactive plant
compounds Database (BPCD)
Information and structures for >13,000
constituents of ≈300 commonly used
herbs. >2500 compounds active against
≈80 targets. Full set of structures
Ehrman et al. (2007a,b) http://www.chemtcm.com/
Ethnopharmacological Database
(GPNDBTM)
100,000 natural products (3D
structures), biological activities,
ethnopharmacological data. In-house
database of Greenpharma S.A.
Do and Bernard (2006) http://www.greenpharma.com
Traditional Chinese Medicine
Information Database (TCM-ID)
Information on 1197 formulas, 1098
herbs and 9852 constituents in relation
to TCM diagnosis and prescription.
Some structures
Chen et al. (2006) http://tcm.cz3.nus.edu.sg/group/tcm-
id/tcmid.asp
TCM  data only
Dictionary of Chinese Herbs TCM herbal formulas, speciﬁcity,
toxicity and side effects. No structures
– http://Alternativehealing.org/Chinese herbs
dictionary.htm
Traditional Chinese Medicine Database
System
Bibliographic database (TCMLARS), and
Chinese herb database (TCDBASE) in
addition to other data
– http://www.cintcm.com
TCMGeneDIT Information on relations between TCM
and gene regulation, protein-protein
interactions and biological pathways
Fang et al. (2008) http://tcm.lifescience.ntu.edu.tw/
TCM  Knowledge Based Grid TCM herb database, literature
database, traditional Tibetan herb
database. No structures
– http://www.cintcm.com
TCM  Assistant TCM herbs, herbal formulas, diseases
and patent prescriptions. No structures
– http://www.tcmassistant.com
Phytochemical data only
PhytochemDB Chemical composition of 1278 taxa
(>19,000 constituents), including
Chinese herbs. No structures
– http://ukcrop.net/perl/ace/search/PhytochemDB
Dr. Duke’s Phytochemical and
Ethnobotanical Databases
Information on phytochemicals from
>1000 plants, including Chinese herbs.
No structures
Duke (1992) http://www.ars-grin.gov/duke/
Dictionary of Natural Products (DNP) Major source of chemical information
on natural products, including some
biological sources, and
pharmacological and toxicological
data. Full set of structures
– http://dnp.chemnetbase.com
Table 2
A catalogue of databases holding information on the structures of known and potential protein targets of the phytochemical constituents of herbs used in TCM.
Database Content Source URL
Therapeutic Target Database (TTD) Information on 1894 targets, 5028
drugs, diseases, and pathways
Zhu et al. (2010) http://xin.cz3.nus.edu.sg/group/ttd/ttd.asp
Potential Drug Target Database (PDTD) Information on 830 targets, protein
and active site structures, biological
functions, diseases and pathways
Gao et al. (2008) http://www.dddc.ac.cn/pdtd/
Protein Data Bank Information of 70,000+ protein
structures determined by single crystal
X-ray diffraction or high ﬁled 1H NMR
studies
Berman et al. (2000) http://www.rcsb.org/pdb
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uite dramatically, and the phytochemical classes found within
ndividual plants are often characterised by a large variety of closely
elated constituents, many of which have been investigated in
etail over the past few decades. A catalogue of the databases cur-
ently available and relevant to computational studies of CHM is
resented in Tables 1 and 2. The databases listed include those
olding (a) botanical information on TCM herbs, and the compo-
ition of TCM formulae and their usage, (b) information on the
hytochemical constituents of plants (including those used in TCM
nd others), and (c) information on known and potential protein
argets of the phytochemical constituents of herbs used in TCM.
he databases containing category (a) and/or category (b) data are
hown in Table 1; those containing data in category (c) are shown
n Table 2.
Of the TCM and natural product databases that have been con-
tructed that provide information relevant to in-silico studies of
HM (Table 1), the majority (ten out of the total of ﬁfteen) appear
o contain either limited or no chemical data on the phytochemical
onstituents of the herbs, and would clearly, therefore, have limited
tility in any bioinformatics/cheminformatics research.
As regards the protein/target databases holding information rel-
vant to in-silico CHM studies (Table 2), the principle resource –
ince it contains details of all publicly available protein 3D struc-
ures – is provided by the Protein Data Bank (PDB; Berman et al.,
000). The Therapeutic Target Database (TTD; Zhu et al., 2010) and
he Potential Drug Target Database (PDTD; Gao et al., 2008) are
ore focused resources, providing details of proteins of speciﬁc
nterest in development of new drug therapies and/or studies of
echanisms of drug/CHM phytochemical action.
In assessing the utility of the various databases available, the
ollowing considerations were made:
The availability of a database is important to consider, and
although sources which are not publicly available are unlikely
to be of interest to most people, such databases might neverthe-
less be of interest to researchers who are perhaps on the lookout
for unusual information, and who might, therefore, be prepared
to negotiate with the database authors directly.
Databases that are ‘live’ and curated must be held as superior to
those that are static and unsupported.
Databases that are reported in a peer-reviewed scientiﬁc pub-
lication must likewise be held as superior to those that are
undocumented.
Databases should ideally embody a range of data, including not
just chemical structure data but also information on TCM usage,
toxicology data, known or predicted target(s), etc.  It is also to be
preferred that the database cater for complex Boolean searches,
allowing, for example, for a search for all compounds based a
given natural product scaffold found in plants with a speciﬁc TCM
usage.
From a practical point of view it is important to consider the
‘platform’ required by the database (that is, whether it can be
mounted and used on computers running UNIX, or Windows,
etc.). For intensive use, a CD/DVD version of a database is much
preferable to a database accessed online (via the internet).
It is important to distinguish between databases where users can
output a list or batch ﬁle of chemical structures from a search,
and those where this is not possible. It is often the case, for exam-
ple, particularly with commercial databases, that structures have
to be downloaded individually, and this must be regarded as a
signiﬁcant limitation/deﬁciency.
The nature of the available chemical data held within the database
is crucial to consider since this will impose limitations on the
type(s) of database search and/or the type(s) of analysis that
can be performed. It is important to discriminate between those
databases that hold only 2D chemical structure data, those thatrmacology 140 (2012) 526– 534
hold 3D data on single conformers, and those that hold 3D data
on multiple conformers. It is also important to discriminate those
databases in which compound stereochemistry is unequivocally
deﬁned and those where stereochemistry is unspeciﬁed.
4. Evaluation criteria for CHM databases
With due consideration of all the points noted above, the WP4
in-silico work group formulated a set of quality evaluation cri-
teria/content and functionality check list for CHM databases The
check list is shown in Table 3, and feature criteria relating to the
database content (C1–C11), the versatility of Boolean searches that
are catered for (C12–C14), the nature of the allowed chemical struc-
ture output (C15–C16), and the availability of associated reports in
peer-reviewed publications (C17). These various features might be
used (a) in deﬁning the content to be acquired in creation of a new
CHM database, and (b) as a means for users to judge the utility of
an existing CHM database. The database features deemed (by the
authors) to be of greatest importance include:
• those relating to content – particularly in terms of the chemical
structure data held (C1–C11);
• the versatility of Boolean searches that are catered for – the ideal
being that searches involving multiple search ﬁelds are allowed,
one of which is preferably a molecular structure based search
ﬁeld (C12–C14);
• the nature of the allowed chemical structure output – the ideal
being that multiple chemical structures can be output, each in 3D
format (C15–C16).
In view of the fact that several of the databases catalogued
in Table 1 were not available for evaluation by the WP4  in-
silico work group, it was deemed inappropriate to present any
evaluation scores for the databases. Instead, the databases were
simply grouped (without ranking) according to their content. Those
grouped at the top of Table 1 are those considered most useful for
in-silico studies of CHM – in that they contain botanical, TCM and
phytochemical data, including chemical structures. The databases
listed in the second group are those that contain only TCM data,
while those grouped last include only non-speciﬁc botanical and
phytochemical information.
The majority of the databases listed in Tables 1 and 2 do not
contain information relating to the toxicology of TCM, principally
because the commonly used endpoints such as LD50 (either for
individual constituents or for herbal extracts) are of limited value
in understanding the possible side effects of herbs, particularly
those that arise through long term use. While Chinese medicine
has always paid close attention to this sort of information, the only
English-language toxicological database available is that reported
by Bensoussan et al.
5. Types of software for use in computational studies of
CHM
As for the review of databases (above), examples of software
tools relevant to computational studies of CHM were catalogued
using the knowledge and expertise of individual WP4  members
together with information presented in the review by Ehrman et al.
(2010b).
Several categories of software were deemed of relevance in CHM
research. Those of use for virtual screening and/or the identiﬁca-
tion of potential mechanisms of action of CHM constituents were
identiﬁed as:
Ligand based screening programs – Pre-requisite(s) for
use: knowledge of compounds with known activity; use: to
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Table 3
Quality evaluation criteria for CHM databases.
Evaluation criteria Description of criteria
C1 Contains information on CHM usage?
C2 Contains botanical information of plants used in CHM?
C3 Contains toxicological data on CHM phytochemicals?
C4  Contains (known) biological activity data on CHM phytochemicals?
C5  Contains (predicted) biological activity data on CHM phytochemicals?
C6  Contains chemical structure data on CHM phytochemicals?
C7  Contains 2D structures of CHM phytochemicals?
C8 Contains 3D structures of CHM phytochemicals?
C9 Contains data on the molecular mechanism(s) of CHM phytochemicals?
C10 Data on >1000 unique CHM phytochemicals
C11 Database is live, curated and updated?
C12 Database can be queried by chemical structure?
C13 Searches with ≥2 search ﬁelds possible?
C14 Searches can be performed using combinations of search ﬁelds?
C15
Chemical structure(s) can be output in 1D (as SMILES strings)?
Chemical structure(s) can be output in 2D?
Chemical structure(s) can be output in 3D (as single conformers)?
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C16 Facility for (batch) output of multip
C17 Database is reported in an article in
dentify putatively active compounds; tools available: classiﬁca-
ion/regression trees (including Random Forest), linear discrimi-
ant analysis, artiﬁcial neural networks, support vector machines.
Pharmacophore programs – Can be either ligand-based (LB),
r target-based (TB) (the latter being superior/preferable); pre-
equisite(s) for use: 3D structures of known ligands to chosen targets
LB), or known 3D structures of target protein(s), and ideally known
D structure(s) of known complex(es)) (TB); use: to identify puta-
ive active compounds; programs available: LigandScout (Wolber
nd Langer, 2005), Schrödinger’s Phase program (Dixon et al., 2006)
nd Accelrys’s Discovery Studio® Catalyst.
Docking programs – Pre-requisites for use: known 3D struc-
ure(s) of target proteins; use: to ‘dock’ potential small molecule
igands into protein active sites, optimising their topographical and
hemical complementarity, and scoring their interaction. Programs
vailable: FlexX (Rarey et al., 1996), Gold (Jones et al., 1997), Dock
Shoichet and Kuntz, 1993), Glide (Halgren et al., 2004), MolDock
Thomsen and Christensen, 2006), AutoDock (Goodsell et al., 1996)
nd LigandFit (Venkatachalam et al., 2003).
Other relevant types of software tool were identiﬁed as:
Pattern recognition software – Use: post-screening analy-
es (involving dimensionality reduction); algorithms employed:
rinciple components analysis, multi-dimensional scaling, self-
rganising maps, and various forms of cluster analysis.
Proteomics and/or genomics data visualisation and analysis
ools – Use: application speciﬁc programs for statistical processing
nd visualisation of data output from DNA micro-array experi-
ents, MS  proteomics experiments, etc.
. Factors for consideration in the choice of in-silico tools
sed in the study of CHM
In consideration of the in-silico tools that are readily available
or use in CHM research, and the factors that might mitigate against
heir productive application in such research it should be noted that
lthough the majority of tools are readily available and, for the most
art, easy to operate, they are not suitable for those lacking the
ppropriate computing background. In-silico tools should ideally
ot, therefore, be used by non-specialists, since almost everyone
an obtain an output from a computational program, but – if not
arefully produced/checked – the output obtained could be mean-
ngless. That said, manuals/handbooks should of course be available
nd should be exhaustive. In silico approaches and tools that facil-
tate and complement molecular biology studies constitute a fastD (as conformer libraries)?
emical structures
er reviewed journal
moving research area. Direct interaction with experts from that
area thus provide the best option for CHM experimentalists to max-
imise the value of in-silico predictions.
In assessing the utility of the various in-silico tools available for
the study of CHM, the hardware platform is relevant, since high
throughput screening approaches require a very efﬁcient use of
RAM and a stable operating system, and UNIX/MacOSX/Linux oper-
ating systems may  be more suitable in this regard than Windows
– albeit that these are perhaps not as intuitive to set up and use as
those implemented under Windows. In addition, it should be noted
that the utility of web-based resources – although in many ways
very convenient – is critically dependent on their availability.
It is not necessary that the algorithms to be used have been vali-
dated speciﬁcally for use in CHM research; and users should count it
sufﬁcient that the methods they propose to use have been validated
on other data sets that are analogous to those to be investigated in
the CHM studies. That said, it must also be noted that in-silico stud-
ies of natural products may  not necessarily be conducted in quite
the same way as those focused on synthetic chemical libraries –
given that the two  classes of compound have rather different pro-
ﬁles of chemical properties (Feher and Schmidt, 2003).
7. Reports of target-oriented in-silico screening of bioactive
material in CHM
The following sections present a précis of the research reported
over the period 2000–2010 wherein in-silico methods have been
used in studies of the bioactive materials in CHM.
7.1. Virtual screening of Chinese herbs for drug discovery
Several studies dealing with the virtual screening (VS) of CHM
constituents, most of which have been published within the last
ﬁve years, have sought to employ various computational methods
to identify potential ligands for protein targets of pharmaco-
logical/therapeutic interest. The screening techniques employed
include pharmacophore search, molecular docking, and screening
by means of chemical descriptors and ﬁngerprints.
There are several cases reported in which compounds found in
Chinese herbs have been identiﬁed as likely inhibitors of speciﬁc
enzymes or receptors, and these predicted activities have subse-
quently been conﬁrmed experimentally. (Such studies are clearly
of greater interest than those where the in-silico predictions are not
subsequently tested by experiment.)
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It is particularly of interest to note here that for several of the
eported studies signiﬁcant information leading to the selection
f appropriate plant material was derived from a consideration of
he plants’ use(s) in TCM – thus testifying to the importance of
thnopharmacological data in VS studies.
Molecular docking studies have shown that sieboldigenin binds
o the active site of soybean lipoxygenase (SLOX), and this com-
ound was later found to inhibit SLOX with an IC50 of 38 M, as well
s reducing carageenan-induced paw oedema (Khan et al., 2009).
ieboldigenin is a spirostane sterol found in various species of Smi-
ax including Smilax glabra (tufuling) which is used in TCM as a
heat clearing’ herb, employed largely for arthritic joint pain and
kin disease.
In like manner, leucovorin was discovered as a potential anti-
IV agent by screening Chinese natural products using a molecular
ngerprint based on the HIV protease inhibitor, saquinavir. Molec-
lar dynamics studies subsequently conﬁrmed the favourable
inding of this compound to the protease active site (Gao et al.,
007).
Combined molecular ﬁngerprint studies and docking were
lso responsible for the discovery of aurantiamide acetate, from
rtemisia annua (qinghao), as an inhibitor of severe acute respira-
ory syndrome coronavirus main proteinase (SARS-CoVMpro; Wang
t al., 2007).
In a search for ways to prevent surface bioﬁlm formation, Zeng
t al. (2008) performed VS studies of quorum sensing inhibitors of
seudomonas aeruginosa.  Fifty-one TCM compounds with known
ntibacterial activity were docked into the active site of the tran-
cription activation factor TraR. In vitro screening of eight of the
igh scoring compounds subsequently showed that Pseudomonas
eruginosa growth was effectively inhibited by baicalein and that
his compound acted synergistically with ampicillin.
Rollinger et al. used protein-based pharmacophores to screen
or natural product inhibitors of acetylcholinesterase (AChE) and
yclooxygenase (COX). By this means they identiﬁed scopoletin
s a potential AChE inhibitor and sanggenons as a potential COX
nhibitor, and these predictions were then proved correct through
n vitro studies (Rollinger et al., 2004, 2005).
In other VS studies of CHM consitituents the screening was
ither carried out without reference to TCM usage or else it afforded
redictions of potential ligands which were not then substantiated
xperimentally.
Paoletta et al. (2008) selected three Chinese herbal constituents
hich were identiﬁed as potential aromatase inhibitors by VS based
n molecular descriptors, using known phytochemical inhibitors
n training, and then docked each of these into the active site
f human aromatase. The three compounds studied were the
avonoids myricetin, liquiritigenin and gossypetin. Liquiritigenin
as shown to have a lowest binding energy. Subsequent in vitro
xperiments conﬁrmed these in-silico predictions, with liquiriti-
enin showing the highest potency – exhibiting an IC50 of 0.34 M
nd thus presenting a 10-fold increase in inhibitory activity over
he ﬁrst generation inhibitor, aminoglutethimide.
Guided by the TCM use of Epimedium spp. as tonics for
yang invigoration’, Chen et al. sought to identify constituents of
hese herbs which might mimic  the phosphodiesterase 5 (PDE5)
nhibitory effect of sildenaﬁl (Chen et al., 2009). They used pharma-
ophores, docking and QSAR methods. Several potential inhibitors
ere identiﬁed and some of these – similar in structure to ES-03b
 showed docking scores which were comparable to that shown by
nother known PDE5 inhibitor taladaﬁl (Chen et al., 2009).
Three similar studies have been reported involving in-silico
creening of Chinese herbs for compounds active against vari-
us kinases that present as targets for cancer therapy – these
eing the aurora-A kinase, polo-like kinases and KDR kinase (Yu
t al., 2007; Deng et al., 2008; Wang et al., 2008). In all threermacology 140 (2012) 526– 534
studies, a similar methodology was employed, using pharma-
cophores derived from known inhibitors which were used to screen
the CNPD (Shen et al., 2003) (in the case of the aurora-A and polo-
like kinase studies) and the TCMD (Qiao et al., 2002) (for the KDR
kinase study). The various hits obtained were then ﬁltered using the
Lipinski rules, regression analysis predictions of IC50, and molecular
docking to relevant protein targets. In the case of the KDR kinase,
a pterocarpan glucoside was  identiﬁed as a hit from the TCMD,
and this was  found by experiment to have a dissociation constant
of 30 M.
7.2. Searching for multi-target ligands in Chinese herbs
Virtual screening studies have also been performed in the search
for single phytochemicals with the potential to inhibit a variety of
functionally/pathologically related targets, and also in searches for
‘cocktails’ of ligands, each of which is predicted to inhibit one of the
targets in a series of (pathologically related) targets of interest.
Huang et al. (2007) have shown that several constituents of
plants used in the Chinese formula Xuefu zhuyu tang could present
as inhibitors of targets relevant to the treatment of cardiovascu-
lar disease. ‘Drug-like’ compounds with acceptable ADME proﬁles
were ﬁrst identiﬁed by Lipinski ﬁltering, and these were then
docked to a number of targets with known signiﬁcance in cardio-
vascular disease, including renin, angiotensin-converting enzyme
(ACE), VEGFR, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) and P-glycoprotein (Pgp). A total of 283 compounds were
obtained as possible inhibitors of all the selected protein targets.
Out of the 11 herbs studied, the majority were identiﬁed as possible
inhibitors of more than one target. Moreover, 10 of the herbs were
shown to possess constituents with the potential to inhibit two or
more targets, and 50% of these showed the potential to inhibit ﬁve
targets.
Ehrman et al. (2007b) have used multiple decision trees to ﬁsh
for compounds in Chinese herbs on the basis of structural similarity
to known phytochemical inhibitors of targets involved in sev-
eral disease processes, including inﬂammation, HIV and diabetes;
they used Random Forest models to discriminate phytochemical
inhibitors from 8000+ compounds found in 240 herbs. Target com-
pounds that could not be distinguished from the known inhibitors
for a given target on the basis of three different RF models (each
employing a different set of molecular descriptors), were ﬂagged
as potential inhibitors of that target. Despite stringent selection
criteria, around 62% of the plant species were hit at least once, with
50% of these predicted to have constituents active against two or
more targets. Literature searches performed to corroborate these
predictions, subsequently showed that 29% of the predicted classes
within these herbs were supported by recent data, with ∼80% of
publications providing new information distinct from that used in
constructing the RF models.
The same research team later reported protein-based screen-
ing studies (Ehrman et al., 2010a),  employing multiple PDB
ligand–receptor complexes, to identify possible ligands four major
anti-inﬂammatory targets – COX, p38 MAP  kinase (p38 MAPK), c-
Jun terminal NH2 kinase (JNK), and phosphodiesterase 4 (PDE4).
A conformational database of Chinese herbal constituents was
ﬁrst screened using LigandScout pharmacophores (derived through
analyses of ∼60 PDB entries). Resulting hits were subsequently
docked into the relevant target proteins, and the docking scores
compared against the median binding energy for the crystal ligands
for that target. Analysis of the cumulative scores for compounds
from distinct phytochemical classes within each herb led to the
identiﬁcation of the 100 plants most likely to yield mimics com-
parable in potency to the known PDB ligands. Further analysis
revealed that the Chinese formulas in which these herbs were
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nﬂammatory conditions.
.3. Inverse docking and target ﬁshing
Inverse docking and target ﬁshing are in-silico screening tech-
iques that are used to identify protein targets ab initio. These
echniques can thus be viewed as particularly pertinent in studies
f phytochemicals. Indeed, two of the computer programs avail-
ble have been speciﬁcally developed Chinese medicine in mind,
o aid in elucidating the targets of TCM constituents. The ﬁrst of
hese, INVDOCK (Chen and Zhi, 2001), is similar as regards dock-
ng methodology to Kuntz’s DOCK program (Shoichet and Kuntz,
993); it makes use of a database of protein cavities derived from
DB entries, and query compounds are tested for ﬁt against some or
ll of these cavities to identify potential targets. The algorithm uses
 shape matching alignment of the query compound to each protein
avity, with torsion optimisation and energy minimisation using
he AMBER force ﬁeld then employed to reﬁne the ﬁt. Protein cavi-
ies are deﬁned using overlapping spheres following the approach
f Kuntz et al. (Shoichet and Kuntz, 1993), and the database now
olds ∼9000 entries. Validation of the methodology, using phyto-
hemicals with known targets (including ginsenoside Rg1, baicalin,
uercetin, emodin, catchin and allicin), identiﬁed ∼50% of the tar-
ets for which experimental data exist (Chen and Ung, 2002; Chen
t al., 2003). INVDOCK has also been used to identify possible tar-
ets of the cytotoxic compound ganoderic acid D from the Chinese
ungus Ganoderma lucidum (lingzhi), following investigation of its
ffects on expression of 21 different proteins. The results obtained
uggest that it might bind eight of these receptors directly (Yue
t al., 2008).
TarFisDock (Li et al., 2006) is another inverse docking program,
nd makes use of a similar methodology to INVDOCK. This pro-
ram uses a protein database constructed from the PDB (with each
ntry comprising residues within 6.5 A˚ of a known ligand), with the
ctive site deﬁned by spheres as in INVDOCK. The docking of query
ompounds against the database sites is again based on Kuntz’s
OCK algorithm. TarFisDock (http://www.dddc.ac.cn/tarﬁsdock/)
s designed for use with the PDTD (Gao et al., 2008) and cur-
ently holds over 1100 entries covering 830 known or potential
rug targets, each target being linked to information on biolog-
cal function and disease. Users can access the program via the
nternet, with query compounds uploaded, and the database then
earched for candidate targets via a web interface available at
ttp://www.dddc.ac.cn/pdtd/. Successful applications of the pro-
ram reported to date include the identiﬁcation of a Helicobacter
ylori target for the natural product N-trans-caffeoyltyramine in
he enzyme peptide deformylase – this compound, and one if its
erivatives, subsequently being shown to be potent inhibitors of
he enzyme with IC50 values of 10.8 and 1.25 M,  respectively (Cai
t al., 2006).
Greenpharma’s ‘reverse pharmacognosy’ represents another
nverse docking approach (Do and Bernard, 2006), very similar to
NVDOCK and TarFisDock, but differing in its use of an in-house
atabase of ethnopharmacological data. Where pharmacognosy
eeks to identify bioactive compounds from plants based on extrac-
ion and assay, reverse pharmacognosy seeks to screen targets
nd diseases from individual compounds. In part this is achieved
hrough use of compound and target databases linked by the dock-
ng program Selnergy – the use of which successfully identiﬁed
-viniferin as an inhibitor of phosphodiesterase 4 (-viniferin being
 stilbene found in Sophora spp. that are commonly used in TCM).
An alternative, related strategy used in identifying targets of
hytochemical involves the screening of query compounds against
harmacophore models of PDB ligands. Such screening is signif-
cantly faster than molecular docking, and thus provides a rapidrmacology 140 (2012) 526– 534 531
means to ﬁlter out compounds that are not direct mimics of the
ligands from which the pharmacophore model is generated. This
approach does have the drawback, however, that compounds that
might ﬁnd alternative modes of binding to the selected protein
targets will not be identiﬁed as hits. The ﬁrst use of this type of
PDB-based pharmacophore method for target ﬁshing for plant con-
stituents was reported by Rollinger et al. (2009).  In this study, 16
constituents of Ruta graveolens were screened against a database
containing 2208 pharmacophores. In vitro screening against three
targets – AChE, HRV coat protein and cannabinoid receptor type-2
(CB2) – showed a close degree of congruity between the best hits
and their respective IC50 values.
7.4. In-silico tools for proteomics, genomics and metabonomics
data visualisation and analysis
The advent of information rich “omic” techniques has provided
powerful new research tools for use in the study of CHM. Using
genomic, proteomic or metabonomic analysis, it has become pos-
sible to examine simultaneous molecular effects that result when
using chemical mixtures as in CHM, affording new opportunities
to study biological effects holistically, rather than by following the
classical reductionistic approach – a new vision which goes beyond
single molecule pharmacology and target speciﬁcity, embracing the
entire equilibrium of a biological system undergoing simultaneous
perturbations. Such an approach can be considered more feasible
to investigate the effects of multichemical mixtures on a plurality
of biological targets, as in CHM formulae (for a review see Buriani
et al., 2012).
Using such a strategy a multitude of experimental data can be
obtained that need to be handled both in terms of multichemical
identiﬁcation and pathophysiological correlations. With the help of
bio-informatics, speciﬁc software and databases have been devel-
oped in order to exploit the large amount of raw data derived from
omics techniques and allow correlation of the multiple compo-
nents of a given phytocomplex with its biological effects (Wang
et al., 2011, 2012). This systems biology approach thus integrates
powerful information rich technologies, computational tools and
knowledge bases, making it possible to establish links between
molecular patterns, biological functions and a wide range of human
diseases and pharmacological interventions (Auffray et al., 2009).
In particular, high-throughput omics techniques require several
bioinformatics and knowledge-assembly tools for data processing,
analysis, integration and interpretation using a top-down system
biology approach (Naylor and Chen, 2010).
When using omics techniques, raw data are produced mostly
from microarrays and mass spectrometry or NMR, depending on
the technique used, and subsequent to data processing – which
often needs multivariate analysis – sets of qualitative and quanti-
tative data are obtained indicating patterns of induced molecular
perturbations. In-silico tools can be used to assist in molecular iden-
tiﬁcation, and databases as well as speciﬁc search software are
available to assist in this task. These include the METLIN and Mass-
Bank databases for metabolomics (Sana et al., 2008; Wolf et al.,
2010; Horai et al., 2010), and human protein and peptide databases
for proteomics (Choi et al., 2008; Klimek et al., 2008; Ding et al.,
2008; Wang et al., 2011, 2012).
Following analysis, the affected molecular networks can be
identiﬁed and the observed perturbations correlated to a given
pharmacotoxicological effect. This last correlation step is of utmost
importance in order to exploit the full potential of information
rich data resulting from the application of omics techniques. Sev-
eral databases have been made available that can be used for
guided analysis, while others can be applied to untargeted and
genome-wide or metabolome-wide association studies (Smith and
Newton-Cheh, 2009; Chadeau-Hyam et al., 2010). These databases
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llow data mining, integrated correlations, and modelling of bio-
hemical pathways, thus providing a platform of translational
edicine that can also be used for CHM research (Li et al., 2010).
olecular databases can be thus used to identify unknown metabo-
ites or peptides, to identify structure from known elemental
omposition, or to determine the biological function of a speciﬁc
olecule.
The catalogue of databases and software developed for genome-
cale metabolic reconstructions is ever-increasing, and many of
hese utilities are freely available for academic use. The databases
nd software that are currently available have been extensively
eviewed elsewhere (Kouskoumvekaki and Panagiotou, 2011;
iehn et al., 2011; Kamath et al., 2011), and the following section
rovides just a few selected examples.
The Human Metabolome Database (HMDB) is considered the most
complete bioinformatics and chemoinformatics medical infor-
mation database (Kouskoumvekaki and Panagiotou, 2011) with
more than 6800 metabolite entries; it is fully searchable with
tools for viewing, sorting metabolites and pathways, and pro-
vides customised, clickable metabolic maps, as well as disease
information (Wishart et al., 2009).
BiGG, Biochemical Genetic and Genomic knowledge base, is a
metabolic reconstruction of human metabolism using both
genetics and literature-based data to assess whether a reaction
is present, providing conﬁdence level data and Boolean rela-
tionships between genes, proteins and reactions (Schellenberger
et al., 2010).
The Small Molecule Pathway Database (SMPDB) is an interactive,
visual database containing a limited number of small-molecule
pathways found in humans, most of which cannot be found in any
other pathway database. The SMPDB is used in metabolomics,
transcriptomics and proteomics studies (Frolkis et al., 2010).
Genomics Portals provides a database of human, mouse, and rat
genomics data with basic analytical visualisation tools (Shinde
et al., 2010).
Examples of proteomic databases include GPDE, Griss Proteomics
Database Engine,  PRIDE, Proteomics IDEntiﬁcations database, and
PeptideAtlas (Griss et al., 2011).
Some databases are dedicated to speciﬁc ﬁelds of study. For
example, T3TB, the Toxin and Toxin-Target Database, provides
descriptions, mechanisms of action, and information on toxins
and toxin-targets (Lim et al., 2010). CEBS, Chemical Effects in
Biological Systems, is an integrated public repository focused
on toxicogenomics, integrating data describing histopathologi-
cal and biological measures with microarray and proteomics data
(Waters et al., 2008).
Even though the introduction of omics techniques in CHM
esearch is relatively recent and is not yet widely disseminated
mong scientists in the ﬁeld, meaningful examples of the appli-
ation of a systems biology approach can be found in the current
iterature, and the results are suggestive of a great potential for
pplication of omics and related bioinformatic techniques in the
tudy of both Chinese syndromes and phytocomplexes from tradi-
ional Chinese medicine.
The “Connectivity Map” (CMAP) has been successfully used
o examine the biological effects of Chinese formulae. CMAP is
 database used for the identiﬁcation of functional connections
etween drugs, genes and diseases (Lamb, 2007). Using gene
xpression microarrays it was possible to compare the gene expres-
ion signatures of MCF-7 cells treated with the Chinese medicine
ormulae Si-Wu-Tang, with those of 1309 compounds present in
he CMAP database, thus allowing the matching of the formula-
nduced pattern with that of estradiol-treated cells, suggesting a
hytoestrogenic effect (Wen  et al., 2011).rmacology 140 (2012) 526– 534
Using a similar approach, Cheng et al. tested the effects of
15 different Chinese herbal formulae on mouse kidney and liver,
analysing DNA expression on microarrays. The molecular signa-
tures of the formulae were compared with those from drugs, or
disease states in three different databases. In addition to using
CMAP to compare the formulae-regulated genes with those of
known drugs, the Genetic Association Database was  used for com-
paring with gene expression patterns from disease states (Becker
et al., 2004) and the Environment, Drugs and Gene Expression
(EDGE) database to compare with the effect patterns resulting from
exposures to chemicals (Hayes et al., 2005). The results showed
numerous matches allowing predictions on both the pharmacolog-
ical effects and the toxicological potential of the formulae (Li et al.,
2010).
Transcriptomics was  also used to analyse the effects of San-
Huang-Xie-Xin-Tang and its herbal components on the HepG2
human hepatoma cell line. Using the Molecular Signature Database
website, TIGR Multiexperiment Viewer and BiblioSphere Path-
way  Edition software, it was  found that the formula displayed an
antiproliferation pattern via the p53 pathway, signalling an effect
that was  also shown to be attributable primarily to a single herbal
component (Cheng et al., 2008).
Pro-apoptotic and pro-inﬂammatory pathways were shown to
be activated when using the Chinese herbal formula PHY906 on
tumour bearing mice. In this case, gene functions were congregated
into pathways and networks using Ingenuity Pathways Analysis
(IPA) (Wang et al., 2011, 2012).
IPA was  also used to analyse microarrays for gene expression
in mice fed with Ginkgo biloba.  The results showed alterations in
several pathways, suggesting implications of both pharmacotoxi-
cological and pharmacokinetic interest when using Ginkgo biloba
(Guo et al., 2010).
A metabonomic study was performed analysing urine col-
lected from rats fed with Morning Glory (Pharbitis purpurea) seeds,
to study the nephrotoxicity induced by this plant – commonly
used in TCM. Urine was  analysed by ultra-performance liquid
chromatography/mass spectrometry (UPLC/MS) and mass spectra
were interpreted with the aid of biochemical databases, such as
KEGG, METLIN, and SciFinder and eight endogenous metabolites as
biomarkers were found to be signiﬁcantly changed in the urine (Ma
et al., 2010).
The ‘Kidney-Yang Deﬁciency syndrome’ induced by high doses
of hydrocortisone and the therapeutic effects of the dried rhizome
of Drynaria fortunei, traditionally used for treating the syndrome,
were studied using a metabonomic approach. Urine samples were
analysed with UPLC/MS and identiﬁcation of potential markers, was
sought using the HMDB, METLIN, Massbank, PubChem and KEGG
databases. The work provided indications on biochemical path-
ways which correlated with the syndrome-related dysfunctions in
energy metabolism as well as the efﬁcacy of the Drynaria treatment
(Lu et al., 2011).
A proteomics analytical approach was used to study the effect
of Salvia miltiorrhiza on vascular atherosclerotic lesions, using an
in vitro smooth muscle cell model. Two-dimensional electrophore-
sis coupled with mass spectrometry was used to analyse proteins
under oxidative stress and treatment with the herbal extract. The
MetaCore software was then used to investigate the biological path-
ways involved and it was found that Salvia miltiorrhiza exerts its
protective effect by acting on the scavenging of ROS and subsequent
modulation of protein carbonylation to inhibit cell proliferation
(Hung et al., 2010).
A large amount of experimental data generated by high-
throughput techniques is available through various public
repositories. Knowledge about transcriptional regulation, molec-
ular interaction networks and metabolic pathways is rapidly
expanding thanks to the innovative system biology approach,
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nformation rich omics technology and computer assisted analysis.
n this rapidly evolving context the experimental study of multiple
arget, multichemical pharmacologic effects with phytocomplexes
s in CHM, can greatly beneﬁt from this new holistic scientiﬁc
ision.
. Conclusions
In-silico tools are best applied in CHM research as a means: to
eek out potential mechanisms of action of their constituents; to
dentify putative new leads for drugs; and to summarise and/or
isualise the complex patterns embedded within the output gen-
rated through associated ‘omics studies. Given the complexity of
HM, and the ensuing difﬁculties in performance of the relevant
xperimental work, in-silico studies clearly offer an economical and
fﬁcient way of exploring the problem landscape and they can thus
id in the formulation of appropriate hypotheses for subsequent
esting in (in vitro and/or in vivo) laboratory studies.
The utility and choice of in-silico screening tools are dependent
n the reason(s) for their use and/or the nature of the output to be
enerated. The knowledge of the computational specialist is essen-
ial in guiding decisions made here, and it is imperative that the
ools should be applied in CHM research through close collabora-
ion between computational specialists and CHM experimentalists.
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